



**HAL**  
open science

## Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa

Mael Baudoin, Maame Esi Woode, Marie Libérée Nishimwe, Maud Lemoine, Babacar Sylla, Charles Kouanfack, Raoul Moh, Moussa Seydi, Nicolas Rouveau, Alain Attia, et al.

### ► To cite this version:

Mael Baudoin, Maame Esi Woode, Marie Libérée Nishimwe, Maud Lemoine, Babacar Sylla, et al.. Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa. *Liver International*, 2020, 40 (11), pp.2643-2654. 10.1111/liv.14613 . inserm-03121819

**HAL Id: inserm-03121819**

**<https://inserm.hal.science/inserm-03121819>**

Submitted on 26 Jan 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title: Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for**  
2 **patients with chronic hepatitis C in Central and West Africa**

3

4 **Authors:** Mael BAUDOIN<sup>1</sup>, Maame ESI WOODE<sup>2</sup>, Marie Libérée NISHIMWE<sup>1</sup>, Maud LEMOINE<sup>3</sup>,  
5 Babacar SYLLA<sup>4</sup>, Charles KOUANFACK<sup>5,6</sup>, Raoul MOH<sup>7</sup>, Moussa SEYDI<sup>8</sup>, Nicolas ROUVEAU<sup>9</sup>,  
6 Alain ATTIA<sup>10</sup>, Karine LACOMBE<sup>11,12</sup>, Sylvie BOYER<sup>1</sup>

7 **Affiliations:**

8 <sup>1</sup>Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé &  
9 Traitement de l'Information Médicale, Marseille, France; Email : [mael.baudoin@inserm.fr](mailto:mael.baudoin@inserm.fr);  
10 [marie.nishimwe@inserm.fr](mailto:marie.nishimwe@inserm.fr); [sylvie.boyer@inserm.fr](mailto:sylvie.boyer@inserm.fr)

11 <sup>2</sup> Centre for Health Economics, Monash University, Melbourne, Australia; Email:  
12 [Maame.Woode@monash.edu](mailto:Maame.Woode@monash.edu)

13 <sup>3</sup>Imperial College, London, United Kingdom; Email: [m.lemoine@imperial.ac.uk](mailto:m.lemoine@imperial.ac.uk)

14 <sup>4</sup>IMEA, Paris, France; Email : [syllababacar2000@yahoo.fr](mailto:syllababacar2000@yahoo.fr)

15 <sup>5</sup> Faculté de médecine et des sciences Pharmaceutiques, Université de Dschang, Cameroun; Email :  
16 [charleskouanfack@yahoo.fr](mailto:charleskouanfack@yahoo.fr)

17 <sup>6</sup>Hôpital de Jour, Hôpital Central de Yaoundé, Cameroun;

18 <sup>7</sup>MEREVA, PACCI Abidjan, Côte d'Ivoire; Email : [rmoh73@gmail.com](mailto:rmoh73@gmail.com)

19 <sup>8</sup> Service des Maladies infectieuses et Tropicales, CHU Fann, Dakar, Sénégal; Email :  
20 [seydi.moussa@gmail.com](mailto:seydi.moussa@gmail.com)

21 <sup>9</sup> ANRS, Paris, France; Email : [nrouveau@gmail.com](mailto:nrouveau@gmail.com)

22 <sup>10</sup> Service d'hépatologie, CHU Yopougon, Abidjan, Côte d'Ivoire; [attia\\_alain@yahoo.fr](mailto:attia_alain@yahoo.fr)

23 <sup>11</sup> Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP,  
24 Paris, France; Email : [karine.lacombe2@aphp.fr](mailto:karine.lacombe2@aphp.fr)

25 <sup>12</sup> APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France.

26

27 **Article Type:** Original Research

28 **Word count for main body of manuscript:** 4028 words

29 **Total number of Figures:** 3

30 **Total number of Tables:** 2

31 **Correspondance:** Sylvie Boyer, Aix Marseille Université, INSERM, IRD, SESSTIM, Faculté de  
32 Médecine, 27 Bd Jean Moulin, 13 005 Marseille, France ; Email : [sylvie.boyer@inserm.fr](mailto:sylvie.boyer@inserm.fr) ; Tel : +33 4  
33 13 73 22 72

34 **ORCID:**

35 Sylvie Boyer: 0000-0002-7567-5200

36 **Abbreviations:** CC, Compensated cirrhosis; CHC, Chronic hepatitis C; CI, Confidence Intervals;  
37 DAAs, Direct Acting Antivirals; DC, Decompensated cirrhosis; GDP, Gross domestic product; HCC,  
38 Hepatocellular carcinoma; HCV, Hepatitis C virus; HE, Health expenditures; HIC, High-income  
39 countries; LIC, Low-income countries; LY, Life-years; LYS, Life-years saved; OOP, out-of-pocket  
40 payments; PCR, polymerase chain reaction; SSA, Sub-Saharan Africa; SVR, Sustained virologic  
41 response; WHO, World Health Organization.

42

43 **Conflict of interest disclosure:**

44 K.L. reports personal fees and non-financial support from GILEAD, personal fees and non-financial  
45 support from ABBVIE, personal fees and non-financial support from JANSSEN, grants, personal fees  
46 and non-financial support from MSD, outside of the submitted work. All other authors report no conflict  
47 of interest in relation to this study.

48

49 **Funding statement:**

50 This research was supported by the Agence National de Recherche sur le VIH/SIDA – Inserm ANRS  
51 (Grant number 12342). The funding source had no role in the study design, data collection, data analysis,  
52 data interpretation or writing of this manuscript.

53

54 **Acknowledgments:**

55 We would like to thank all the members of the ANRS 12311 TAC study group for their full support in  
56 the present study. We also thank all the trial participants, the staff at the participating sites as well as  
57 Sylvie Legac and Gabrièle Laborde-Balen at the ANRS Cameroon and Senegal sites for their support  
58 with the data collection. Our thanks also to Gwenaëlle Maradan for the monitoring of the socioeconomic  
59 data collection, to Arlette Kouame Tolayad, Patrick Kouabenan, Marietou Kante and Bara Nibilla who  
60 collected the socioeconomic data, and to Jude Sweeney for the English revision and editing of the  
61 manuscript.

62

63 **Ethics approval statement**

64 The national Ethic Committees of the three study countries (Cameroon, Côte d'Ivoire and Senegal)  
65 approved the protocol for the study.

66

67 **Patient consent statement**

68 Not applicable.

69

70 **Permission to reproduce material from other sources**

71 Not applicable.

72

73 **ABSTRACT (word count: 249)**

74 **Background:** In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We  
75 estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon,  
76 Côte d'Ivoire and Senegal using Markov model combining data from the literature with estimates of  
77 direct antiviral agents (DAAs) effectiveness in West and Central Africa.

78 **Methods:** Disease progression was simulated with and without treatment in fictive cohorts of patients  
79 "diagnosed" with CHC in Cameroon (n=3224), Côte d'Ivoire (n=9748) and Senegal (n=6358). Lifetime  
80 treatment benefits were assessed using i) life-years saved (LYS), ii) life-years (LY) avoided in  
81 compensated cirrhosis (CC), decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC), iii)  
82 comparison of the proportions of patients at each disease stage with and without treatment. Probabilistic  
83 and determinist sensitivity analyses were performed to address uncertainty.

84 **Results:** Sofosbuvir-based treatment would save [mean, 95% Confidence Intervals] 3.3 (2.5;5.7) LY  
85 per patient in Cameroon, 2.7 (2.1;4.8) in Côte d'Ivoire and 3.6 (2.8;6.3) in Senegal. With treatment,  
86 approximately 6% (1%) of the patients still alive in each of the study countries would be in the CC (DC)  
87 health state 11 (15) years after CHC diagnosis, versus 15% (5%) without treatment. Scenario analysis  
88 showed earlier diagnosis and treatment initiation would dramatically improve LYS and morbidity.

89 **Conclusion:** Sofosbuvir-based treatment could significantly reduce CHC-related mortality and help  
90 control CHC-related liver disease progression in West and Central Africa. However, the goal of disease  
91 elimination necessitates a substantial decrease in DAAs prices, greater political commitment, and  
92 increases in both national and external health expenditures.

93

94 **Keywords:** hepatitis C; direct-acting antiviral agents (DAAs); markov simulation; low-income  
95 countries; Africa.

96

97 **Lay summary**

98 We estimated that the treatment of chronic hepatitis C (CHC) with direct antiviral agents could lead to  
99 a 75% reduction in the number of CHC-related liver complications 15 years after CHC diagnosis, and a  
100 73% reduction in mortality in West and Central Africa. Mortality and morbidity outcomes could be  
101 further significantly improved if early diagnosis and treatment were implemented. Our findings provide  
102 a strong argument for universal treatment of CHC patients using DAAs in West and Central Africa.

103

## 104 INTRODUCTION

105 Viral hepatitis is a global public health issue affecting 325 million people in 2015, including 71 million  
106 with the hepatitis C virus (HCV)<sup>1</sup>. The burden of HCV infection is especially high in Sub-Saharan Africa  
107 (SSA), which accounts for 14% of the total number of people infected with HCV worldwide<sup>2</sup>. HCV  
108 viremic prevalence is unevenly distributed in this region, with the highest prevalence rates in Central  
109 (2.1%) and West (1.3%) Africa<sup>2</sup>.

110 HCV causes both acute and chronic infection. While acute infection is usually asymptomatic and  
111 resolved spontaneously without treatment in 15-45% of infected persons, 60–80% of those infected  
112 develop chronic hepatitis C (CHC)<sup>3</sup>. In the absence of timely diagnosis and adequate treatment, CHC  
113 may progress to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)<sup>4</sup>. In addition, the risk of  
114 mortality associated with liver disease is high, especially in SSA where most people are diagnosed at  
115 advanced stages and where access to treatment is limited<sup>5</sup>. HCV is responsible for an estimated 21% of  
116 cancer deaths worldwide, corresponding to 167,000 deaths in 2015, including 8,000 and 31,000 deaths  
117 in Central and West Africa, respectively<sup>6</sup>. In 2016, the World Health Organization (WHO) developed a  
118 global health strategy to eliminate viral hepatitis with two main objectives to be reached by 2030:  
119 reducing the number of new cases of viral hepatitis by 90%, and reducing viral hepatitis-related mortality  
120 by 65%<sup>1</sup>. Antiviral treatment using Direct Acting Antivirals (DAAs) is one of the core interventions  
121 needed to reach these targets.

122 In 2014, the advent of second generation DAAs, which have a short treatment duration (8 to 16 weeks),  
123 radically changed the hepatitis C landscape. DAAs are highly effective, with sustained virologic  
124 response (SVR) rates estimated between 93% and 97% in trials conducted in high-income settings<sup>7–11</sup>.  
125 In addition, they are very well tolerated, making them easier to manage than interferon-based regimens.

126 The 2016 WHO guidelines recommending sofosbuvir/daclatasvir, sofosbuvir/ledipasvir or  
127 sofosbuvir/ribavirin for the treatment of CHC in adults<sup>12</sup> were updated in 2018, with pangenotypic  
128 DAAs regimens achieving SVR rates of over 85% across all seven major HCV genotypes<sup>13</sup>.

129 The short-term efficacy and tolerability of these regimens were recently reported in West and Central  
130 Africa<sup>14</sup> and in East Africa<sup>15</sup>. Despite their effectiveness and increasing low-cost availability in most  
131 countries, DAAs remain inaccessible for the large majority of patients with CHC living in SSA, where  
132 the treatment rate was estimated to be as low as 2% of diagnosed cases in 2015<sup>1</sup>.

133 To provide further evidence of the benefits of introducing DAAs-based treatments into National  
134 Hepatitis Programs in West and Central Africa, we used a modelling approach to assess the long-term  
135 clinical outcomes of treating CHC patients with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire  
136 and Senegal. We discussed the affordability of these treatments in all three countries, by considering  
137 government health expenditures (HE), private HE and patient willingness-to-pay.

## 138 **METHODS**

### 139 **Study design**

140 A Markov cohort model was developed to simulate lifetime CHC progression and to assess the long-  
141 term clinical benefits of DAAs in terms of mortality and morbidity. With near-zero CHC treatment rates  
142 in the study countries<sup>1</sup>, we decided to use the status-quo (i.e. no HCV treatment, whether DAAs or  
143 Interferon-based) as a comparator.

144

### 145 **Target population**

146 We simulated CHC progression, with and without treatment, in fictive cohorts of patients diagnosed  
147 with CHC in Cameroon, Côte d'Ivoire and Senegal. Cohort sizes were estimated for each country using  
148 the national population size, chronic HCV prevalence and diagnosis rates. Given that CHC is generally  
149 diagnosed late in the study countries - usually after the initial appearance of symptoms - we assumed a  
150 mean age of 50 years at model entry<sup>14,15</sup>. Patients were infected with genotypes 1, 2, or 4 and had no  
151 other viral coinfections, history of liver decompensation, or HCC. The proportion of women was 53%  
152 in Senegal, 50% in Cameroon and 49% in Côte d'Ivoire, which corresponds to the demographic structure  
153 of the population at 50 years of age in these countries<sup>16-18</sup>.

154

### 155 **Outcome measures**

156 We compared the following outcomes with and without treatment: mortality assessed using life-years  
157 (LY), morbidity assessed using LY with compensated cirrhosis (CC), decompensated cirrhosis (DC)  
158 and HCC as well as the evolution over time of the number (%) of patients in each disease stage.  
159 Treatment benefits were assessed in life-years saved (LYS) and LY avoided in CC, DC and HCC stages.

160

### 161 **Model description**

162 The structure of the model is depicted in [Figure 1](#). Markov models with a similar structure have been  
163 widely used in the literature for simulating CHC progression<sup>19</sup>.

164 The initial distribution of patients in the different health states defined according to the natural history  
165 of CHC (including fibrosis stage measured with the METAVIR scoring system F0 to F3, CC, DC and  
166 HCC) were as follows: 7.6% were in F0, 39.2% in F1, 26.2% in F2, 18.6% in F3 and 8.4% in CC<sup>20</sup>. At  
167 model entry, all patients had a detectable VL. Cycle durations were set to one year to reflect both the  
168 relatively slow progression of the disease and data availability, except the first cycle whose duration  
169 was set to 24 weeks (i.e., 12 weeks of treatment and 12 weeks of follow-up post-treatment). We assumed  
170 that transitions between health states occurred in the middle of the cycles using half-cycle corrections<sup>21</sup>.

171 Disease progression over cycles depended on whether or not patients in the fictive cohorts received  
172 sofosbuvir-based regimens and on whether or not they achieved SVR at the end of the treatment cycle.

173 In the cohorts without treatment, all patients with uncontrolled VL progressed to more advanced disease  
174 stages according to the natural evolution of the infection.

175 In the cohorts with treatment, patients with mild fibrosis (F0, F1, F2, F3) or CC were all eligible for  
176 treatment in accordance with 2016 WHO guidelines<sup>12</sup>. At the end of the treatment cycle, patients in the  
177 fictive cohorts either achieved SVR (cured) or did not (not cured). Although the first cycle duration  
178 (corresponding to the treatment and follow-up post-treatment periods) was relatively short (i.e. 24  
179 weeks), we assumed that the disease could progress to a more advanced stage for some patients during  
180 that cycle. In the subsequent cycles, we assumed that apart from patients in the CC and DC health states  
181 at the end of the treatment cycle, cured patients did not progress to a more advanced disease stage<sup>4</sup>. In  
182 addition, as fibrosis improvements observed after treatment in cured patients cannot be attributed with  
183 certainty to histological recovery, we made the conservative hypothesis that no fibrosis reversal occurred  
184 in those patients<sup>22,23</sup>. We also assumed that cured patients had a risk of reinfection in the subsequent  
185 cycles but were not newly treated<sup>13</sup>. Reinfected or uncured patients had uncontrolled VL and therefore  
186 progressed through the different disease stages as untreated patients.

187 In all cohorts, patients had a risk of non-CHC-related death in all health states, corresponding to the  
188 “natural mortality” rate. Additionally, patients in the F3, CC, DC and HCC health states had a risk of  
189 CHC-related death.

190

## 191 **Model inputs**

192 All parameters were derived from the literature by prioritizing data from SSA countries where available.  
193 The HCV viremic prevalence and diagnostic rate were obtained from Chan et al. (2017)<sup>24</sup> for Cameroon,  
194 and from the WHO 2017 report<sup>1</sup> for Senegal and Côte d’Ivoire.

195 DAAs treatment effectiveness was obtained from the ANRS 12311 TAC trial which included 120 CHC  
196 patients treated either with sofosbuvir and ledipasvir (for genotypes 1 and 4) or with sofosbuvir and  
197 ribavirin (for genotype 2)<sup>14</sup>. As SVR rates were not significantly different across genotypes, countries  
198 or HIV co-infection status, we considered an overall 89.2% [95% Confidence Intervals (CI): 84.5; 93.8]  
199 probability of treatment success in the model, irrespective of regimen, genotype, country or HIV co-  
200 infection status.

201 In the absence of SSA country-specific data, transition probabilities between fibrosis stages without  
202 treatment were obtained from a meta-analysis<sup>25</sup>, while probabilities of transition from F3 to advanced  
203 stages (CC, DC and HCC) were derived from Dienstag et al. (2011)<sup>26</sup>. Transition probabilities  
204 (irrespective of viremic status) from CC (to DC and to HCC) and from DC (to HCC) came from Nahon



205 et al. (2018)<sup>4</sup> and Planas et al. (2004)<sup>27</sup>, respectively. Annual probabilities of death associated with CC  
206 and DC were obtained from Dienstag et al. (2011)<sup>26</sup> and Planas et al. (2004)<sup>27</sup>, respectively.

207 As therapeutic options for patients with HCC living in the study countries were very limited, we  
208 estimated the annual probability of death using HCC survival data for patients who did not receive  
209 specific treatment for liver cancer in a multi-country observational study conducted in SSA<sup>28</sup>.

210 All-cause mortality probabilities according to age and country were obtained from WHO mortality  
211 tables<sup>29</sup>. The probability of reinfection or relapse in patients achieving SVR after treatment was sourced  
212 from a meta-analysis including studies conducted in mono-HCV infected patients living in high-income  
213 countries (HIC) who had no specific risk factors for reinfection<sup>30</sup>. All parameter values and their sources  
214 are presented in [Table 1](#) (See also the Appendix 1 for further details).

215

### 216 **Internal consistency**

217 We tested the internal validity of our model i) by simulating a treated cohort with an SVR equal to zero  
218 (all results should be identical for the treated and untreated cohorts); and ii) by assuming that the  
219 probabilities of death associated with liver complications in F3, CC, DC and HCC stages were equal to  
220 zero (life expectancy at 50 years is expected to be close to that of the general population of the same  
221 age).

222

### 223 **Sensitivity analysis**

224 A probabilistic sensitivity analysis was conducted to assess parameter uncertainty in the model, in  
225 accordance with international guidelines<sup>31</sup>. Model parameters were sampled from predefined  
226 distributions over 1000 simulations (See the Appendix 1 for further details).

227 In addition, a deterministic sensitivity analysis was conducted to explore specific scenarios and to take  
228 heterogeneity into account (i.e. specific subgroups). First, we simulated long-term clinical outcomes in  
229 the fictive cohorts of HIV/HCV co-infected patients assuming they had a higher risk of HCV reinfection  
230 than mono-infected patients<sup>30</sup>. Second, we used a younger fictive cohort (35 years) to estimate the effect  
231 of early diagnosis. In addition, cohorts with different initial disease stages were simulated to assess the  
232 impact of initiating DAAs at different stages. Based on the TAC trial data<sup>14</sup>, we considered a lower SVR  
233 rate (estimated at 78.6%) for patients at CC stage. Third, we simulated a scenario where patients were  
234 treated using the most recent pangenotypic DAAs regimen, sofosbuvir/daclatasvir, recommended in the  
235 2018 WHO guidelines<sup>13</sup>. As no data on SVR was available for this regimen in SSA, the SVR rate was  
236 estimated at 90.8% using data from a French national cohort<sup>32</sup> adjusted for a potential lower  
237 effectiveness in SSA compared with HIC, as suggested by results from the TAC and SHARED trials<sup>14,15</sup>.

238 Analyses were performed using R, version 3.6.0 (packages *markovchain*<sup>33</sup>).

## 239 RESULTS

### 240 Internal consistency of the model

241 When we simulated a treated cohort with an SVR equal to zero, results for the two cohorts (treated and  
242 untreated) were identical. In the second extreme value analysis, life expectancy at 50 years was  
243 estimated at 22.6 years in Cameroon, 20.9 in Côte d'Ivoire and 24.2 in Senegal, which is in line with  
244 WHO estimates on life expectancy in the general population of the same age<sup>29</sup>.

245

### 246 Base-case analysis

247 At the current diagnostic rate<sup>1,24</sup>, the number of patients diagnosed with CHC was estimated at 3,224 in  
248 Cameroon, 9,748 in Côte d'Ivoire and 6,358 in Senegal. [Figure 2](#) illustrates the impact of sofosbuvir-  
249 based treatment on liver-related mortality due to CHC over the lifetime of the cohorts in each study  
250 country. Without treatment, the share of CHC-related mortality as part of global mortality was 36.5%,  
251 33.2% and 39.5% in Cameroon, Côte d'Ivoire and Senegal, respectively, versus 9.8%, 9.1% and 10.5%  
252 with treatment, respectively. Accordingly, 863, 2,350 and 1,843 deaths, respectively, could be avoided  
253 with treatment, corresponding to a 73% reduction of liver-related mortality in the population diagnosed  
254 with CHC.

255 [Table 2](#) shows, for each cohort in each country: i) life expectancy at 50 years (assessed using the mean  
256 number of LY per patient in the cohorts with and without treatment) and LYS per patient with treatment,  
257 ii) morbidity assessed using the mean number of LY per patient at the CC and DC stages with and  
258 without treatment, and the mean number of LY avoided in the CC and DC stages per patient with  
259 treatment. LYS [95% CI] with treatment were estimated at 3.3 [2.5; 5.7] per patient in Cameroon, 2.7  
260 [2.1; 4.8] in Côte d'Ivoire and 3.6 [2.8; 6.3] in Senegal. In addition, the mean number of LY spent in the  
261 most advanced stages in cohorts with treatment decreased by a factor of approximately 2, 3 and 10 in  
262 the CC, DC and HCC stages, respectively, compared with patients not treated. We therefore estimated  
263 that, on average, treatment resulted in between 1.3 to 1.6 LY avoided and 0.4 to 0.5 LY avoided per  
264 patient in the CC and DC stages, respectively, depending on the country.

265 [Figure 3](#) illustrates the number (%) of patients with cirrhosis (CC and DC) over the cohorts' lifetime in  
266 the study countries. Without treatment, the number of patients with CC and DC reached a maximum  
267 approximately 11 and 15 years after CHC diagnosis, respectively. In the untreated cohorts,  
268 approximately 15% of patients still alive in each of the study countries after 11 years had CC compared  
269 with 6% in the treated cohorts. After 15 years, approximately 5% of patients still alive in the treated  
270 cohorts had DC compared with 1% in the treated cohorts. The number of patients with CC reduced by  
271 approximately 55% after 11 years and the number of patients with DC by approximately 75% after 15  
272 years. Finally, after 20 years, the estimated proportion of patients with HCC represented 0.6%-0.7% of

273 patients still alive in the untreated cohorts versus 0.1% in the treated cohorts in the three countries. This  
274 indicates a significant decrease of 87% (Supplementary [Table A1](#)).

275

## 276 **Sensitivity analysis**

277 Results from the deterministic sensitivity analysis are presented in supplementary [Tables A2 to A9](#) and  
278 in supplementary [Figures 1 and 2](#), which show the mean [95% CI] number of LY avoided in CC and  
279 DC stages per patient. For the fictive cohorts of HIV/HCV co-infected patients, mortality and morbidity  
280 outcomes considerably improved with treatment but clinical benefits were smaller than in the base-case  
281 due to higher reinfection rates in this population. LYS [95% CI] were only 2.6 [1.7;5.6] per patient in  
282 Cameroon, 2.2 [1.3;4.9] in Côte d'Ivoire and 2.8 [1.8;6.0] in Senegal. Furthermore, patients spent 0.4 to  
283 0.5 additional LY at the CC stage and 0.1 additional LY at the DC stage compared with the base-case  
284 (Table A2).

285 Early diagnosis and treatment initiation (at 35 years) would save 5.9 to 7.9 additional LY compared with  
286 the base-case. Depending on the country, 1.1 to 1.4 additional LY in the CC stage and 0.4 to 0.5  
287 additional LY in the DC stage would be avoided compared with the base-case ([Table A3](#)).

288 When all the patients of the cohorts started treatment at F0, F1 or CC, treatment benefits were smaller  
289 than in the base-case, for both mortality and morbidity ([Tables A4, A5 and A8](#)). Conversely, treatment  
290 benefits were larger than in the base-case when we assumed that all patients started treatment at the F2  
291 or F3 stage ([Tables A6-A7](#)). When all patients initiated treatment at the F3 stage, the LYS per patient  
292 increased to 6.3 to 8.0 depending on the country, and LY avoided in the CC and DC states varied  
293 between 3.2 to 3.6 years and 0.9 to 1 years, respectively.

294 Finally, when considering the most recent pangenotypic DAAs regimen (sofosbuvir/daclatasvir),  
295 mortality and morbidity outcomes were quite similar to the base-case ([Table A9](#)).

296

297

## 298 **DISCUSSION**

299 This modelling study provides the first assessment of the long-term clinical benefits of DAAs treatment  
300 in patients diagnosed with CHC living in West and Central Africa.

301 The number of people living with CHC is estimated at 88,358 in Cameroon, 165,776 in Côte d'Ivoire  
302 and 108,134 in Senegal. At current diagnosis and treatment rates<sup>1,24</sup>, an estimated 3,224, 9,748 and 6,358  
303 people have been diagnosed, but only 0.12% to 0.31% of them benefit from treatment (including  
304 interferon-based treatment)<sup>13</sup>.

305 Our findings showed that treating all patients currently diagnosed with CHC with DAAs in the three  
306 study countries could dramatically decrease both CHC-related mortality and morbidity. We estimated  
307 that DAAs would avoid 863, 2,350 and 1,843 deaths in Cameroon, Côte d’Ivoire and Senegal,  
308 respectively, and save 2.7-3.6 LY per patient once diagnosed. Furthermore, as treatment stops disease  
309 progression (except at the most advanced stages), the number of LY spent in the CC, DC and HCC  
310 stages would decrease by approximately 2, 3 and 10 times, respectively, compared with the status-quo.  
311 Sensitivity analysis also indicated that early diagnosis and treatment initiation dramatically improved  
312 survival and reduced morbidity, compared with the base-case. Treatment benefits were the highest when  
313 all patients started treatment at the F2 or F3 stage.

314

315 To date, DAAs short-term effectiveness in SSA has been assessed in only two pilot trials with a  
316 relatively small number of patients in each (300 in Rwanda<sup>15</sup> and 120 in Côte d’Ivoire, Cameroon and  
317 Senegal<sup>14</sup>). Recently, modelling studies - all in high- or middle-income countries - also predicted the  
318 impact of DAAs treatment on CHC-associated long-term disease burden and mortality. In a recent study  
319 conducted in China, simulations for a cohort of 10,000 CHC patients over their lifetime, highlighted that  
320 various DAAs regimens would reduce the incidence of CHC-related liver sequelae and mortality  
321 significantly more than interferon/ribavirin-based regimens<sup>34</sup>. Our findings are also consistent with those  
322 of a study assessing the long-term effectiveness of different HCV treatment strategies in Egypt which  
323 showed that immediate treatment of patients at stages F1 to F3 was more effective than delaying  
324 treatment until more advanced stages<sup>35</sup>.

325

## 326 **Public health policy recommendations**

327 In order for DAAs to have any impact in poor resource settings, a number of barriers need to be removed.  
328 These are mainly linked to suboptimal HCV screening and to the high costs of DAAs.

329

### 330 ***Hepatitis C screening***

331 Scaling-up access to hepatitis C testing and earlier CHC diagnosis requires the availability of simplified  
332 and low-cost diagnostic tools adapted to resource-limited settings. Current diagnosis relies on a two-  
333 step procedure involving antibodies detection followed, if tests prove positive, by the quantification of  
334 HCV ribonucleic acid using real-time quantitative polymerase chain reaction (PCR) assay. This  
335 technique is costly (between 55 and 110 US\$/test) and requires trained lab technicians and equipment,  
336 which is currently only available in a small number of reference laboratories in SSA. Furthermore, even  
337 when PCR testing is available, the two-step procedure generates loss to follow-up because of the  
338 additional time and large costs incurred by patients<sup>36</sup>. Innovative means to both diagnose CHC cheaply

339 and quickly using a single test are needed<sup>37</sup>. Existing alternatives include dried blood spot tests and  
340 point-of-care and HCV core antigen measurements. The latter is an indirect marker of viral replication  
341 with good performance already demonstrated in the SSA setting<sup>38</sup>. In addition, a test-and-treat public  
342 health approach should be favoured, as recommended by the 2018 WHO guidelines<sup>13</sup>, in order to ensure  
343 that patients with a positive diagnosis are promptly treated.

344

### 345 *Diagnosis and treatment costs*

346 Although dramatic decreases in DAAs prices have been obtained in low-income countries (LIC)  
347 following Gilead's DAAs tiered pricing policy and the entry of generics<sup>39</sup>, the diagnosis and treatment  
348 of CHC is still very expensive<sup>40</sup>. A 12-week sofosbuvir/ledipasvir regimen manufactured by Gilead costs  
349 approximately US\$1150 in the study countries, while generic drugs could become available for only  
350 US\$140 according to the 2017 Médecins Sans Frontières report<sup>41</sup>. Data on costs collected in the TAC  
351 trial in the same countries showed that the global cost for treating patients with DAAs (including  
352 examinations and consultations) ranges from US\$1503 per patient in Côte d'Ivoire to US\$1692 in  
353 Cameroon<sup>42</sup>. Treating all patients currently diagnosed with CHC in the three study countries with DAAs  
354 would therefore imply a total cost of approximately US\$5.4 million in Cameroon, US\$14.6 million in  
355 Côte d'Ivoire and US\$10.3 million in Senegal. Furthermore, if the WHO target of treating 80% of CHC  
356 patients is to be reached, the costs involved will be much higher (US\$140 million in Cameroon, US\$199  
357 million in Côte d'Ivoire and US\$119 million in Senegal). The fundamental issue is whether countries  
358 and patients could afford to pay these costs.

359 In our study countries, health systems are mainly funded by private HE through out-of-pocket payments  
360 (OOP) which represent 70%, 40% and 51% of the total HE in Cameroon, Côte d'Ivoire and Senegal<sup>43</sup>,  
361 respectively. Total current HE is estimated at US\$1500 million in Cameroon, US\$1611 million in Côte  
362 d'Ivoire and US\$816 million in Senegal, with the government's share estimated at US\$195, US\$419  
363 and US\$269 million, respectively.

364 According to current patterns for financing health in the study countries, patients would incur direct  
365 OOP for CHC treatment costs of US\$1185 in Cameroon, US\$601 in Côte d'Ivoire and US\$828 in  
366 Senegal. Considering that the per capita gross domestic product (GDP) is US\$1374, US\$1534 and  
367 US\$1269 in the respective countries, privately paying for health treatment is clearly impossible for most  
368 patients.

369 Data from the TAC trial also indicated that over 75% of patients were willing to pay for diagnosis,  
370 treatment and/or care (See Appendix 2). However, when probed further about the amount they were  
371 willing to pay, the median ranged from US\$126 in Côte d'Ivoire to US\$220 in Cameroon. Such amounts  
372 would cover only 8 to 13% of the costs of CHC treatment in the three study countries.

373 If governments were to bear the total costs of CHC treatment alone, treating all patients diagnosed with  
374 CHC in the three countries would imply a relatively low increase in current government HE (i.e., from  
375 2.8% in Cameroon to 3.8% in Senegal). However, if the WHO target of treating 80% of the patients  
376 living with CHC is to be reached, the additional resources required will be much greater, specifically  
377 1.5 to 1.6 times current government HE in the studied countries.

378 These data suggest that the WHO target cannot be met in these countries without i) a large decrease in  
379 DAAs prices through the development of the production and wider use of generics ii) political  
380 commitment and increased national HE to meet the target of at least 15% of GDP as set out in the Abuja  
381 declaration<sup>44</sup>, iii) global health financing mechanisms, including the integration of hepatitis C epidemic  
382 control strategies within organisations tackling HIV, such as the Global Fund to Fight AIDS,  
383 Tuberculosis and Malaria.

384

### 385 **Study limitations**

386 Our study has limitations. First, a number of model parameters are not specific to SSA. This is especially  
387 true for transition probabilities, which were obtained from studies conducted in HIC. In SSA, where  
388 access to specialized care for liver complications is limited, disease progression and mortality may occur  
389 faster. This may have resulted in an underestimation of mortality in the absence of treatment and  
390 consequently, an underestimation of DAAs benefits. Furthermore, to estimate the risk of reinfection, we  
391 used data from a meta-analysis including studies conducted in mono-HCV infected patients living in  
392 HIC without specific risk factors for reinfection<sup>30</sup>. This could have resulted in an overestimation of  
393 treatment benefits, as patients living in SSA may have a higher risk of reinfection than mono-infected  
394 patients in HIC, due to a higher risk of iatrogenic infections. To address uncertainty in the model's  
395 parameters, a probabilistic sensitivity analysis was conducted in line with international standards<sup>31</sup>.

396 Second, we extrapolated long-term clinical outcomes using a Markov cohort model which does not  
397 account for HCV transmission. Although we acknowledge that dynamic models may be more  
398 appropriate to assess the full health impact of DAAs, including HCV transmission reduction<sup>45</sup>, we chose  
399 to focus on the estimation of clinical outcomes using a Markov model, which requires fewer hypotheses  
400 and fewer data and is faster to implement. In addition, a limitation of this approach is its inability to  
401 simulate patient trajectories using specific individual risk factors that may affect disease progression  
402 over time. Despite this, Markov models have been widely used in the literature for simulating CHC  
403 progression and treatment effectiveness<sup>46</sup>.

404

405 **Conclusion**

406 Our study provides important information for health policy recommendations on the long-term clinical  
407 benefits of DAAs in West and Central Africa and constitutes a first step towards a full-scale analysis for  
408 SSA. Our findings strongly argue for rapid scale-up of DAAs treatment in this region, and highlight the  
409 need for financial and political commitment and support, from both national governments and  
410 international institutions.

411

412 **Authors' contributions:**

413 Study concept and design: S.B., M.E.W. and K.L.; data acquisition: M.B., M.E.W. C.K., R.M., M.S.,  
414 and A.A.; data analysis and interpretation: S.B., M.B., M.L.N., M.E.W., M.L., K.L.; drafting of the  
415 manuscript: SB; critical revision of the manuscript for important intellectual content: S.B., M.B.,M.L.N.,  
416 M.E.W., M.L., B.S., C.K., R.M., M.S., N.R., A.A. K.L.; statistical analysis: M.B. and M.L.N.; obtained  
417 funding: SB; administrative, technical, and material support: M.L., B.S., R.M., N.R., A.A. and K.L;  
418 study supervision: SB. The corresponding author had full access to all the data in the study and had final  
419 responsibility for the decision to submit for publication.

420

421

422 **References**

- 423 1. WHO. WHO | Global hepatitis report, 2017. WHO. Accessed February 19, 2020.  
424 <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/>
- 425 2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of  
426 hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol.*  
427 2017;2(3):161-176. doi:10.1016/S2468-1253(16)30181-9
- 428 3. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol.* 2014;61(1  
429 Suppl):S58-68. doi:10.1016/j.jhep.2014.07.012
- 430 4. Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma After Direct  
431 Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.  
432 *Gastroenterology.* 2018;155(5):1436-1450.e6. doi:10.1053/j.gastro.2018.07.015
- 433 5. Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. *J*  
434 *Hepatol.* 2017;66(3):645-654. doi:10.1016/j.jhep.2016.10.013
- 435 6. Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary Liver Cancer and  
436 Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level.  
437 *JAMA Oncol.* 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055
- 438 7. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for Previously Untreated Chronic  
439 Hepatitis C Infection. *N Engl J Med.* 2013;368(20):1878-1887.  
440 doi:10.1056/NEJMoa1214853
- 441 8. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for Hepatitis C Genotype 2 or  
442 3 in Patients without Treatment Options. *N Engl J Med.* 2013;368(20):1867-1877.  
443 doi:10.1056/NEJMoa1214854
- 444 9. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and Ribavirin in HCV Genotypes  
445 2 and 3. *N Engl J Med.* 2014;370(21):1993-2001. doi:10.1056/NEJMoa1316145
- 446 10. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for Untreated HCV  
447 Genotype 1 Infection. *N Engl J Med.* 2014;370(20):1889-1898.  
448 doi:10.1056/NEJMoa1402454
- 449 11. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks  
450 for Chronic HCV without Cirrhosis. *N Engl J Med.* 2014;370(20):1879-1888.  
451 doi:10.1056/NEJMoa1402355
- 452 12. WHO. WHO | Guidelines for the Screening, Care and Treatment of Persons with Chronic  
453 Hepatitis C Infection.; 2016:138. Accessed August 14, 2018.  
454 <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/>
- 455 13. WHO. WHO | Guidelines for the care and treatment of persons diagnosed with chronic  
456 hepatitis C virus infection. WHO. Published 2018. Accessed August 24, 2018.  
457 <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/>
- 458 14. Lacombe K, Moh R, Chazallon C, et al. Treatment of chronic hepatitis C GT1,2,4 in  
459 Africa: final results of ANRS TAC trial. CROI, Boston, Massachusetts. Presented at the:



- 460 CROI2018; 2018; Boston, Massachusetts. Accessed July 6, 2019.  
461 [http://www.croiconference.org/sessions/treatment-chronic-hepatitis-c-gt124-africa-final-  
results-anrs-tac-trial](http://www.croiconference.org/sessions/treatment-chronic-hepatitis-c-gt124-africa-final-<br/>462 results-anrs-tac-trial)
- 463 15. Gupta N, Mbituyumuremyi A, Kabahizi J, et al. Treatment of chronic hepatitis C virus  
464 infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. *Lancet*  
465 *Gastroenterol Hepatol*. 2019;4(2):119-126. doi:10.1016/S2468-1253(18)30382-0
- 466 16. Agence Nationale de la Statistique et de la Démographie. La population du Sénégal en  
467 2017. Published 2018. Accessed February 19, 2020.  
468 [http://www.ansd.sn/ressources/publications/Rapport\\_population\\_2017\\_05042018.pdf](http://www.ansd.sn/ressources/publications/Rapport_population_2017_05042018.pdf)
- 469 17. Institut National de la Statistique du Cameroun. Recensement Général de la Population et  
470 de l'Habitat (RGPH). Published 2010. Accessed June 21, 2019. [http://www.statistics-  
cameroon.org/downloads/La\\_population\\_du\\_Cameroun\\_2010.pdf](http://www.statistics-<br/>471 cameroon.org/downloads/La_population_du_Cameroun_2010.pdf)
- 472 18. Central Intelligence Agency. The World Factbook — Age Structure. Accessed August 14,  
473 2018. <https://www.cia.gov/library/publications/the-world-factbook/fields/2010.html>
- 474 19. Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the  
475 Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.  
476 *PharmacoEconomics*. 2016;34(6):551-567. doi:10.1007/s40273-015-0373-9
- 477 20. El-Kamary SS, Mohamed MM, El-Raziky M, et al. Liver fibrosis staging through a  
478 stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis  
479 C infection. *Liver Int Off J Int Assoc Study Liver*. 2013;33(7):982-990.  
480 doi:10.1111/liv.12139
- 481 21. Gray A, Clarke P, Wolstenholme J, Wordsworth S. *Applied Methods of Cost-Effectiveness*  
482 *Analysis in Healthcare*. Oxford University Press.; 2011.
- 483 22. Kutala B, Darrigrand NB, Corinne C, Pierre B, Asselah T, Marcellin P. The impact of  
484 direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related  
485 chronic hepatitis C. *J Hepatol*. 2018;68:S541. doi:10.1016/S0168-8278(18)31338-2
- 486 23. Pietsch V, Deterding K, Attia D, et al. Long-term changes of liver elasticity in HVC-  
487 infected patients with SVR after treatment with direct-acting antivirals. *J Hepatol*.  
488 2018;68:S532-S533. doi:10.1016/S0168-8278(18)31317-5
- 489 24. Chan HLY, Chen CJ, Omede O, et al. The present and future disease burden of hepatitis  
490 C virus infections with today's treatment paradigm: Volume 4. *J Viral Hepat*. 2017;24  
491 Suppl 2:25-43. doi:10.1111/jvh.12760
- 492 25. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression  
493 rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology*  
494 *Baltim Md*. 2008;48(2):418-431. doi:10.1002/hep.22375
- 495 26. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression  
496 in compensated, histologically advanced chronic hepatitis C. *Hepatology Baltim Md*.  
497 2011;54(2):396-405. doi:10.1002/hep.24370

- 498 27. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C  
499 virus-related cirrhosis. A study of 200 patients. *J Hepatol.* 2004;40(5):823-830.  
500 doi:10.1016/j.jhep.2004.01.005
- 501 28. Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of  
502 patients with hepatocellular carcinoma in Africa: a multicountry observational study from  
503 the Africa Liver Cancer Consortium. *Lancet Gastroenterol Hepatol.* 2017;2(2):103-111.  
504 doi:10.1016/S2468-1253(16)30161-3
- 505 29. WHO. Global Health Observatory data repository, life table by country. WHO. Published  
506 2018. Accessed February 19, 2019.  
507 <http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en>
- 508 30. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection  
509 With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic  
510 Review and Meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2016;62(6):683-  
511 694. doi:10.1093/cid/civ948
- 512 31. Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and  
513 uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices  
514 Task Force Working Group-6. *Med Decis Mak Int J Soc Med Decis Mak.* 2012;32(5):722-  
515 732. doi:10.1177/0272989X12458348
- 516 32. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV  
517 genotype 1-mono-infected patients. *J Hepatol.* 2017;66(1):39-47.  
518 doi:10.1016/j.jhep.2016.08.021
- 519 33. Spedicato GA. *Markovchain: Easy Handling Discrete Time Markov Chains.*; 2019.  
520 Accessed July 4, 2019. <https://CRAN.R-project.org/package=markovchain>
- 521 34. Tang H, Wu J, Wu B, Xu X, Ye X, Zhang W. Long-Term Outcomes Associated with  
522 Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C in China. *Value Health.*  
523 2018;21:S65. doi:10.1016/j.jval.2018.07.488
- 524 35. Obach D, Deuffic-Burban S, Esmat G, et al. Effectiveness and cost-effectiveness of  
525 immediate versus delayed treatment of hepatitis C virus-infected patients in a country with  
526 limited resources: the case of Egypt. *Clin Infect Dis Off Publ Infect Dis Soc Am.*  
527 2014;58(8):1064-1071. doi:10.1093/cid/ciu066
- 528 36. Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral  
529 hepatitis in low-resource and decentralized settings. *J Viral Hepat.* 2018;25(2):108-117.  
530 doi:10.1111/jvh.12827
- 531 37. Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. *J Int AIDS Soc.*  
532 2018;21 Suppl 2:e25054. doi:10.1002/jia2.25054
- 533 38. Duchesne L, Njouom R, Lissoc F, et al. HCV Ag quantification as a one-step procedure  
534 in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. *Journal*  
535 *of the International AIDS Society.* Published January 1, 2017. Accessed June 18, 2019.  
536 <https://onlinelibrary.wiley.com/doi/abs/10.7448/IAS.20.1.21446>

- 537 39. Assefa Y, Hill PS, Ulikpan A, Williams OD. Access to medicines and hepatitis C in  
538 Africa: can tiered pricing and voluntary licencing assure universal access, health equity  
539 and fairness? *Glob Health*. 2017;13(1):73. doi:10.1186/s12992-017-0297-6
- 540 40. Chabrol F, Noah Noah D, Tchoumi EP, et al. Screening, diagnosis and care cascade for  
541 viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health  
542 providers coping with uncertainty and unbearable costs. *BMJ Open*. 2019;9(3).  
543 doi:10.1136/bmjopen-2018-025415
- 544 41. Médecins Sans Frontières. Hepatitis C - Not even close. Médecins Sans Frontières Access  
545 Campaign. Accessed June 21, 2019. <https://msfaccess.org/hepatitis-c-not-even-close>
- 546 42. Boyer S, Baudoin M, Nishimwe M, et al. Cost-effectiveness of Sofosbuvir-Based  
547 Hepatitis C regimens in Central and West Africa (ANRS 12342). Presented at the: EASL  
548 Conference; April 11, 2018; Paris, France.
- 549 43. WHO. WHO | Global health expenditure database 2018 update. WHO. Accessed January  
550 16, 2020. [http://www.who.int/health\\_financing/topics/resource-tracking/ghed-update/en/](http://www.who.int/health_financing/topics/resource-tracking/ghed-update/en/)
- 551 44. WHO. WHO | The Abuja Declaration: Ten Years On. WHO. Accessed January 16, 2020.  
552 [http://www.who.int/healthsystems/publications/abuja\\_declaration/en/](http://www.who.int/healthsystems/publications/abuja_declaration/en/)
- 553 45. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and  
554 treatment towards the elimination of hepatitis C: a global mathematical model. *The Lancet*.  
555 2019;393(10178):1319-1329. doi:10.1016/S0140-6736(18)32277-3
- 556 46. Luhn M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations  
557 of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. *Appl Health  
558 Econ Health Policy*. 2016;14(5):527-543. doi:10.1007/s40258-016-0253-2
- 559 47. United Nations. World Population Prospects. Published 2017. Accessed April 29, 2019.  
560 <https://population.un.org/wpp/>
- 561

Tables

**Table 1: Model parameters**

Model parameter(s)	Base-case value	Distribution	95% Confidence Intervals	Source	Further description
<b>Cohort characteristics</b>					
Start age of cohort (years)	50	–	–	14,15	35 years – age considered in scenario analyses
Proportion of women at 50 years		–	–		
<i>Cameroon</i>	0.489			17	
<i>Côte d'Ivoire</i>	0.499			18	
<i>Senegal</i>	0.531			16	
<b>Fibrosis Initial Stages at treatment initiation</b>					
F0	0.076	–		20	Scenario analyses considered alternative distributions where all CHC patients start treatment: i) in F0, ii) in F1, iii) in F2, iii) in F3, iv) in CC.
F1	0.392				
F2	0.262				
F3	0.186				
CC	0.084				
<b>DAAs effectiveness</b>					
SVR12 SOF/RBV or SOF/LDV	0.892	–	[0.845;0.938]	TAC trial <sup>14</sup>	
SVR12 SOF/DCV	0.908	–	[0.860;0.955]	HEPATHER cohort <sup>32</sup>	
SVR12 SOF/RBV or SOF/LDV in cirrhotic patients	0.786	–	[0.524; 0.924]	TAC trial <sup>14</sup>	
<b>Natural history of CHC (in untreated or uncured patients): annual disease transition probabilities</b>					
All stages → non-CHC related mortality	–	–	–	29	Country, sex and age-specific
F0 → F1	0.079	Beta(21.1;234.7)	[0.052;0.119]	25	
F1 → F2	0.059	Beta(88.4;1399.1)	[0.048;0.072]	25	
F2 → F3	0.108	Beta(30.0;238.6)	[0.077;0.152]	25	
F3 → CC	0.077	Beta(14.8;164.1)	[0.047;0.127]	25	
F3 → DC	0.012	Beta(7.0;558.0)	[0.005;0.023] <sup>†</sup>	26	
F3 → HCC	0.011	Beta(7.0;558.0)	[0.005;0.023] <sup>†</sup>	26	
F3 → CHC related mortality	0.008	Beta(0.4;18.7)	[0.003;0.019] <sup>†</sup>	26	
CC → DC	0.041	Beta(99.5;2290.4)	[0.034;0.050] <sup>†</sup>	4	
CC → HCC	0.042	Beta(90.0;2048.7)	[0.034;0.051] <sup>†</sup>	4	
CC → CHC related mortality	0.026	Beta(11.5;407.0)	[0.014;0.045] <sup>†</sup>	26	
DC → HCC	0.068	Beta(37.9;514.7)	[0.049;0.091] <sup>†</sup>	27	
DC → CHC related mortality	0.130	Beta(75.7;489.9)	[0.107;0.163] <sup>†</sup>	27	
HCC → CHC related mortality	0.900	Beta(186.3;19.9)	[0.86;0.94] <sup>†</sup>	28	

<b>Table 1 (continued)</b>					
<b>Model parameter(s)</b>	<b>Base-case value</b>	<b>Distribution</b>	<b>95% Confidence Intervals</b>	<b>Source</b>	<b>Further description</b>
<b>CHC progression after DAAs (in cured patients): annual disease transitions probabilities</b>					
CC → DC	0.023	Beta(14.1;540.5)	[0.014;0.040] <sup>†</sup>	4	
CC → HCC	0.014	Beta(37.9;514.7)	[0.007;0.029]	4	
CC → CHC related mortality	0.026	Beta(11.5;407.0)	[0.014;0.045] <sup>†</sup>	26	
DC → HCC	0.068	Beta(37.9;514.7)	[0.049;0.091] <sup>†</sup>	27	
DC → CHC related mortality	0.130	Beta(75.7;489.9)	[0.107;0.163] <sup>†</sup>	27	
HCC → CHC related mortality	0.900	Beta(186.3;19.9)	[0.86;0.94]	28	
<b>Annual probabilities of reinfection</b>					
- <i>mono-infected</i>	0.002	Beta(13.2;7051.8)	[0.001;0.003]	30	
- <i>HIV co-infected</i>	0.032	Beta(0.2;13.1)	[0.000;0.123]	30	
<b>Epidemiology</b>					
<b>Total population, aged 18-100 (2018)</b>					
<i>Senegal</i>	8318000			47	Population age structure is divided into 5-year classes
<i>Côte d'Ivoire</i>	12752000				
<i>Cameroon</i>	12622600				
<b>Viremic prevalence</b>					
<i>Senegal</i>	1.3%		[1.1%-1.4%]	2	
<i>Côte d'Ivoire</i>	1.3%		[1.1%-1.4%]		
<i>Cameroon</i>	0.7%		[0.5%-0.8%]		
<b>% diagnosed with CHC</b>					
<i>Senegal</i>	6.0%			1	Number of people diagnosed with CHC / number of viremic cases
<i>Côte d'Ivoire</i>	6.0%				
<i>Cameroon</i>	4.0%			24	
<b>% diagnosed with CHC and treated</b>					
<i>Senegal</i>	2.0%			1	Annual number of treated CHC patients / total number of diagnosed cases
<i>Côte d'Ivoire</i>	2.0%				
<i>Cameroon</i>	7.9%			24	
<b>Number of patients eligible for treatment</b>					
<i>Senegal</i>	6358				Total population * viremic prevalence * % diagnosed * (1-% treated)
<i>Côte d'Ivoire</i>	9748				
<i>Cameroon</i>	3224				

<sup>†</sup> 95% Confidence Intervals calculated using the Wilson score formula.

Abbreviations: CHC, Chronic Hepatitis C infection; F0, F1, F2, F3, METAVIR fibrosis stages; CC, Compensated Cirrhosis; DC, Decompensated Cirrhosis; DAAs, Direct Action Antivirals; SVR12, Sustained virologic response 12 weeks after the end of treatment.

**Table 2: Mortality and morbidity in fictive cohorts of CHC patients with and without DAAs treatment (n=3224 in Cameroon, n=9748 in Côte d'Ivoire, n=6358 in Senegal)**

	Cameroon		Côte d'Ivoire		Senegal	
	With treatment	Without treatment	With treatment	Without treatment	With treatment	Without treatment
<b>Life expectancy at 50 years and life years saved per patient with treatment</b>						
Mean [95% Confidence Intervals] life-years per patient	21.2 [20.6;21.4]	18 [14.9;18.8]	19.7 [19;19.8]	16.9 [14.3;17.5]	22.7 [21.8;22.9]	19.1 [15.7;19.9]
Mean [95% Confidence Intervals] life-years saved (LYS) per patient <sup>†</sup>	3.3 [2.5;5.7]		2.7 [2.1;4.8]		3.6 [2.8;6.3]	
<b>Life years spent in CC (DC) and life years avoided in the CC (DC) stages per patient with treatment</b>						
Mean [95% Confidence Intervals] life-years spent in CC per patient	1.2 [1;1.4]	2.7 [1.6;3.3]	1.2 [0.9;1.3]	2.4 [1.5;3.1]	1.3 [1;1.5]	2.9 [1.7;3.7]
Mean [95% Confidence Intervals] life-years in CC stage avoided per patient <sup>‡</sup>	1.4 [0.6;2.0]		1.3 [0.5;1.8]		1.6 [0.6;2.3]	
Mean [95% Confidence Intervals] life-years spent in DC per patient	0.2 [0.1;0.2]	0.7 [0.4;0.9]	0.2 [0.1;0.2]	0.6 [0.4;0.8]	0.2 [0.1;0.3]	0.7 [0.4;0.9]
Mean [95% Confidence Intervals] life-years in DC stage avoided per patient <sup>‡</sup>	0.5 [0.3;0.7]		0.4 [0.2;0.6]		0.5 [0.3;0.7]	


<sup>†</sup> Life-years saved per patient are calculated as the number of life-years per patient with treatment minus the number of life-years per patient without treatment.

<sup>‡</sup> Life-years avoided in the CC (DC) stages per patient are calculated as the number of life-years per patient spent in the CC (DC) stage without treatment minus the number of life-years per patient spent in the CC (DC) stage with treatment.

Abbreviations: CHC, Chronic Hepatitis C infection; DAAs, Direct Acting Antivirals; CC, Compensated Cirrhosis; DC, Decompensated Cirrhosis.

## Figures


**Figure 1: Diagram of the Markov cohort model**



**Legend:** The ovals boxes represent the different health states of the model including fibrosis stage measured by the METAVIR scoring system (F0, F1, F2, F3), CC, DC, HCC and CHC RD. At model entry, all patients have a detectable viral load and are at the F0, F1, F2, F3 or CC stages. The two diamonds represent, respectively, whether patients received treatment (“yes” or “no”) and whether they achieved SVR after treatment or not (if “yes”, they are cured; if “not” they are uncured). Arrows on full lines denote the transitions between health states according to treatment decision and treatment success. Arrows on dashed lines show reinfection in cured patients. The upper part of the diagram, labelled “NATURAL DISEASE PROGRESSION”, describes the progression for patients with uncontrolled viral load (i.e. in absence of treatment, in case of treatment failure or reinfection). The lower part of the diagram, labelled “CURED”, describes the treatment benefits in cured patients (i.e., the disease progression stops except in patients in the CC or DC health state stage at the end of the treatment cycle). In all cohorts, patients had a risk of HCV-related death in all health states, corresponding to the “natural mortality” rate, which depends on age, gender and country. Additionally, patients who were in the F3, CC, DC and HCC health states had a risk of CHC-related death.

*CHC, Chronic Hepatitis C; F0-F3, METAVIR fibrosis stages F0 to F3; CC, Compensated Cirrhosis; DC, Decompensated Cirrhosis; HCC, Hepatocellular Carcinoma; CHC RD, Chronic hepatitis C-related death; SVR: Sustainable Virologic Response.*

**Figure 2: Liver disease-related deaths over lifetime with and without treatment in mono-infected patients diagnosed with chronic hepatitis C in Cameroon (Fig. 2a), Côte d’Ivoire (Fig. 2b) and Senegal (Fig. 2c)**




**Legend:** The numbers (%) above each curve indicate, respectively: i) the number of liver disease-related deaths due to CHC over the cohorts’ lifetime with and without treatment; ii) the share of liver disease-related mortality due to CHC within global mortality with and without treatment.

*CHC, Chronic Hepatitis C.*



**Figure 3 : Evolution over lifetime of the number (% among patients still alive) of patients with compensated cirrhosis and with decompensated cirrhosis in mono-infected patients diagnosed with chronic hepatitis C in Cameroon (Fig. 3a), Côte d'Ivoire (Fig. 3b) and Senegal (Fig. 3c)**



**Legend:** The numbers (%) above each curve indicate, respectively: i) the number (%) of patients with CC 11 years after the diagnosis (with and without treatment), ii) the number (%) of patients with DC 15 years after the diagnosis (with and without treatment). The time-points of 11 and 15 years were chosen as they correspond to the approximate maximum number of patients with CC and DC, respectively (in the cohorts without treatment). CC, *Compensated Cirrhosis*; DC, *Decompensated Cirrhosis*.